📰 Pharmaceutical Intelligence News
Page 6 - Pharmaceutical Intelligence News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharmaceutical Intelligence. Real-time updates on events, politics, business and more.
September 14, 2023
Gavocabtagene autoleucel is under clinical development by TCR2 Therapeutics and currently in Phase II for Ovarian Cancer.
August 28, 2023
Amisulpride is under clinical development by Sumitomo Pharma America and currently in Phase III for Bipolar Disorder (Manic Depression).
August 28, 2023
Linavonkibart is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase I program in Non-Small Cell Lung Cancer.
August 28, 2023
DSP-0038 is under clinical development by Sumitomo Pharma America and currently in Phase I for Alzheimer's Disease.
August 28, 2023
NMRA-511 is under clinical development by Neumora Therapeutics and currently in Phase I for Alzheimer's Disease.
August 28, 2023
DISC-0974 is under clinical development by Disc Medicine and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis).
July 31, 2023
Bitopertin is under clinical development by Disc Medicine and currently in Phase II for Anemia.
July 31, 2023
NPT-189 is under clinical development by Proclara Biosciences and currently in Phase I for Primary Systemic Amyloidosis.
July 31, 2023
FOG-001 is under clinical development by Fog Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer.
July 8, 2023
ABBV-101 is under clinical development by AbbVie and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL).